Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122824 · ClinicalTrials.gov registry record · Phase 3
Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
NCT00122824 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 480 participants.
The verdict
NCT00122824, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
Study Summary
This is a clinical trial assessing duloxetine compared with placebo in patients who have generalized anxiety disorder.
Interventions
- DRUG placebo
- DRUG duloxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00122824
The ClinicalTrials.gov registry entry for NCT00122824 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00122824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00122824 about?
NCT00122824 is a clinical study titled "Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder". This is a clinical trial assessing duloxetine compared with placebo in patients who have generalized anxiety disorder.
What is the current status of trial NCT00122824?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2004-06. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00122824?
The interventions under investigation include: placebo (DRUG), duloxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00122824?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.